A227 VEDOLIZUMAB EXPOSURE ASSOCIATED WITH THE RESOLUTION OF OROFACIAL CROHN’S DISEASE: A CASE REPORT
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Abstract Background Orofacial Crohn’s disease (CD) is a rare and often debilitating manifestation of Crohn’s disease, characterized by deep ulcerations, cobblestone lesions of the buccal mucosa, and hallmark granulomas(1,6). Orofacial Crohn’s disease remains a challenging condition to manage, with limited available data on the use of advanced non-TNF-α therapies (3). Vedolizumab, a gut-selective integrin antagonist, has been shown to be effective for inflammatory bowel disease, but its role in treating orofacial CD has not been fully explored(2,3,5). Aims The aim of this case report is to explore the potential efficacy of vedolizumab in treating orofacial Crohn’s disease, a rare and challenging manifestation of Crohn’s disease, by presenting a clinical case where vedolizumab led to significant resolution of both orofacial and gastrointestinal symptoms. This report aims to contribute to the limited data available on the use of non-TNF-α therapies, such as vedolizumab, in managing orofacial Crohn’s disease and to encourage further studies on its therapeutic role in this context. Methods This is a case report of a 68-year-old female with a 33-year history of ileo-colonic Crohn’s disease developed severe orofacial CD after infliximab discontinuation due to peri-prosthetic infection. She presented with severe vomiting, oral ulcerations, and diarrhea, along with ileal inflammation and gastric outlet obstruction. Physical examination revealed angular stomatitis and cobblestone ulcers in the buccal mucosa and palate. Histopathology confirmed CD with granulomatous inflammation. Initial treatment with dexamethasone mouthwash and budesonide showed minimal improvement. The patient was transitioned to vedolizumab, receiving three induction doses followed by monthly maintenance. Results Within two months of starting vedolizumab, the patient showed significant clinical and endoscopic improvement. By the fourth month, complete healing of the oral ulcerations was achieved, alongside resolution of her gastrointestinal symptoms, including gastric outlet obstruction. Vedolizumab was well-tolerated with no significant adverse effects reported. Conclusions This case demonstrates the potential efficacy of vedolizumab in treating orofacial Crohn’s disease, a rare and challenging presentation of Crohn’s disease. Nonetheless, vedolizumab binds to the α4β7 integrin, blocking its interaction with MAdCAM-1 on the surface of gastrointestinal endothelial cells (5). Since MAdCAM-1 is also expressed in the oral mucosa (4), we believe that vedolizumab may offer a promising alternative for patients with orofacial Crohn’s disease who do not respond to traditional therapies. Further studies are needed to establish its role in managing this condition Funding Agencies None
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle